SWOG clinical trial number
CTSU/E1A11

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Closed
Phase
Abbreviated Title
Rand PIII Bort/Len/Dex (VRD) vs Carfilzomib/Len/Dex (CRD) w/Limited or Indefinite Maint for New MM
Status Notes
The study was permanently closed to accrual by ECOG ACRIN on January 29, 2019.
Activated
02/01/2014
Closed
07/14/2017
Participants
CTSU

Research committees

Myeloma

Treatment

Dexamethasone CC-5013 (Lenalidomide) Bortezomib Carfilzomib

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2020

Carfilzomib, lenalidomide and dexamethasone (KRd) versus Bortezomib, lenalidomide and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase 3 trial

S Kumar;S Jacobus;A Cohen;M Weiss;N Callander;A Singh;T Parker;A Menter;A Yang;B Parsons;P Kumar;P Kappor;A Rosenberg;J Zonder;E Faber;S Lonial;P Richardson;R Orlowski;S Rajkumar J Clin Oncol 38: 2020 (suppl; abstr LBA3); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VERSUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR INITIAL THERAPY OF NEWLY DIAGNOSED MULTIPLE MYELOMA (ENDURANCE): A PHASE 3 TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E1A11)

S Kumar;S Jacobus;A Cohen;M Weiss;N Callander;A Singh;T Parker;A Menter;A Yang;B Parsons;P Kumar;P Kapoor;A Rosenberg;J Zonder;E Faber;S Lonial;P Richardson;R Orlowski;L Wagner;S Rajkumar Lancet Oncology Oct;21(10):1317-1330

PMid: PMID32866432 | PMC number: PMC7591827

Other Clinical Trials

SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
10%
Open
Phase